Saint Alphonsus Health System
Title   The ADAPT Trial
Description  

This is an international, phase 3, randomized trial of Autologous Dendritic cell immunotherapy (AGS-003) Plus standard Treatment of advanced renal cell carcinoma (ADAPT), sponsored by Argos Therapeutics, Inc. Cells collected from a person's own kidney tumor can be combined with AGS-003 to create a personalized, experimental drug. Participants will be randomized to either the control group or the experimental group. The control group will receive sunitinib, the standard and most commonly prescribed treatment, while the experimental group will be given the immunotherapy treatment, AGS-003, plus sunitinib.

IRB Number   13-05
Treatment   Oncology
Inclusion/Notes  

Patients with newly diagnosed, advanced kidney cancer can participate in this research. For more information about cancer research, click here.

Status   Active
Start Date   04/11/2013
Principal Name   Kerry Pulver, MD, PhD
Contact Name   Heather Webb
Fax   (208) 367-3149
Current Trial Type   Phase 3, randomized trial
Phone   (208) 367-6816